Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Mol Genet Metab. 2013 Nov;110(3):241-7. doi: 10.1016/j.ymgme.2013.07.018. Epub 2013 Jul 25.
Abnormal neurodevelopment has been widely reported in combined methylmalonic aciduria (MMA) and homocystinuria, cblC type (cblC disease), but neurodevelopmental phenotypes in cblC have not previously been systematically studied. We sought to further characterize developmental neurology in children with molecularly-confirmed cblC. Thirteen children at our center with cblC, born since implementation of expanded newborn screening in New York State, undertook standard-of-care evaluations with a pediatric neurologist and pediatric ophthalmologist. At most recent follow-up (mean age 50 months, range 9-84 months), of twelve children with early-onset cblC, three (25%) had a history of clinical seizures and two (17%) meet criteria for microcephaly. A majority of children had hypotonia and nystagmus. Twelve out of thirteen (92%) underwent neurodevelopmental evaluation (mean age 41 months; range 9-76 months), each child tested with standardized parental interviews and, where possible, age- and disability-appropriate neuropsychological batteries. All patients showed evidence of developmental delay with the exception of one patient with a genotype predictive of attenuated disease and near-normal biochemical parameters. Neurodevelopmental deficits were noted most prominently in motor skills, with relative preservation of socialization and communication skills. Nine children with early-onset cblC underwent magnetic resonance imaging and spectroscopy (MRI/MRS) at mean age of 47 months (range 6-81 months); common abnormalities included callosal thinning, craniocaudally short pons, and increased T2 FLAIR signal in periventricular and periatrial white matter. Our study further characterizes variable neurodevelopmental phenotypes in treated cblC, and provides insights into the etiopathogenesis of disordered neurodevelopment frequently encountered in cblC. Plasma homocysteine and MMA, routinely measured at clinical follow-up, may be poor predictors for neurodevelopmental outcomes. Additional data from large, prospective, multi-center natural history studies are required to more accurately define the role of these metabolites and others, as well as that of other genetic and environmental factors in the etiopathogenesis of the neurologic components of this disorder.
异常的神经发育在甲基丙二酸血症(MMA)和高胱氨酸尿症、cblC 型(cblC 病)合并症中已被广泛报道,但 cblC 患者的神经发育表型此前并未得到系统研究。我们试图进一步描述经分子确诊的 cblC 患儿的发育神经学特征。在纽约州扩大新生儿筛查实施后,在我们中心就诊的 13 名 cblC 患儿接受了儿科神经科医生和儿科眼科医生的标准护理评估。在最近的随访中(平均年龄 50 个月,范围 9-84 个月),12 名早发型 cblC 患儿中,3 名(25%)有临床癫痫发作史,2 名(17%)符合小头畸形标准。大多数患儿有张力减退和眼球震颤。13 名患儿中有 12 名(92%)接受了神经发育评估(平均年龄 41 个月;范围 9-76 个月),每位患儿均接受了标准化的家长访谈,如有可能,还进行了适合年龄和残疾的神经心理学测试。除了一名基因型预测为疾病减轻和生化参数基本正常的患儿外,所有患儿均表现出发育迟缓的证据。神经发育缺陷主要表现在运动技能方面,社交和沟通技能相对保留。9 名早发型 cblC 患儿在平均年龄 47 个月(范围 6-81 个月)时接受了磁共振成像和光谱检查(MRI/MRS);常见异常包括胼胝体变薄、桥脑前后径短和脑室周围及脑室旁白质 T2 FLAIR 信号增加。我们的研究进一步描述了治疗后的 cblC 中不同的神经发育表型,并深入了解了 cblC 中常见的神经发育障碍的发病机制。在临床随访中常规测量的血浆同型半胱氨酸和 MMA 可能是神经发育结局的不良预测指标。需要来自大型、前瞻性、多中心自然史研究的更多数据,以更准确地定义这些代谢物和其他代谢物以及其他遗传和环境因素在该疾病神经成分发病机制中的作用。
Ophthalmic Genet. 2016-12
Ophthalmology. 2013-10-11
Zhongguo Dang Dai Er Ke Za Zhi. 2015-8
Biomolecules. 2024-4-28
Orphanet J Rare Dis. 2023-9-28
Indian J Pediatr. 2024-7
Front Neurosci. 2023-1-26